01—Abstract
Summary
Summary of the 8-K filed February 20, 2024. Cited figures are marked; the original filing is the authoritative source.
Medtronic's Q3 FY24 (quarter ended January 26, 2024) showed steady top-line momentum.
Revenue reached $8.089 billiona, up 4.7% as reported and 4.6% organic, led by Diabetes (+10.2% organic), Structural Heart & Aortic (+9.6% organic), Core Spine, and Cardiac Pacing, with international markets strong. GAAP diluted EPS was $0.99 (up 8%), while non-GAAP diluted EPS of $1.30 was flat year over year, with an 11-cent (8%) currency headwind. Management raised FY24 guidance: organic revenue growth now 4.75% to 5% (from 4.75%), and non-GAAP EPS to $5.19–$5.21 (from $5.13–$5.19), a 4-cent midpoint increase.
Reported FY24 revenue growth is guided to 2.9%b to 3.3%, reflecting divestitures and currency. The most significant strategic news is the decision to exit the ventilator business and combine the remaining Patient Monitoring and Respiratory Interventions businesses into a single unit, Acute Care and Monitoring (ACM). Management characterized ventilators as increasingly unprofitable and expects existing manufacturers to meet market demand, while Medtronic will honor existing ventilator contracts.
Ventilator sales already fell in the mid-twenties in the quarter. Separately, the 8-K discloses that Robert J.
White, EVP and President of the Medical Surgical Portfolio, will leave on April 26, 2024, as his role is eliminated; his severance is a termination without cause under standard executive practices. Overall, the quarter shows solid revenue execution and cost discipline offsetting inflation, tax, and currency pressures, but flat non-GAAP EPS and the reported-growth gap keep the focus on whether product launches (PFA, Diabetes, Percept RC, Micra AV2/VR2) can drive reliable earnings growth.
02—Key points
Key Highlights
- Q3 FY24 revenue of $8.089B, up 4.7% reported and 4.6% organic; Diabetes (+10.2% organic) and Structural Heart (+9.6% organic) led growth
- GAAP diluted EPS of $0.99 (+8%); non-GAAP diluted EPS of $1.30, flat year over year, with an 11-cent currency headwind
- FY24 organic revenue growth guidance raised to 4.75%–5%; reported growth guided to 2.9%–3.3%
- FY24 non-GAAP diluted EPS guidance raised to $5.19–$5.21 (4-cent midpoint increase)
- Exit of the ventilator business and combination of remaining PMRI units into Acute Care and Monitoring (ACM), aiming to focus investment on profitable growth
- Departure of Robert J. White, EVP and President of Medical Surgical Portfolio, effective April 26, 2024, as the role is eliminated; severance paid under standard executive practices
- Key product approvals including FDA approval for PulseSelect PFA and Percept RC with BrainSense, and CE Mark for MiniMed 780G with Simplera Sync and Micra AV2/VR2
03—Questions
Frequently Asked Questions
Why did non-GAAP EPS stay flat if revenue grew?
Non-GAAP diluted EPS of $1.30 was flat year over year despite 4.6% organic revenue growth. Management cited an 11-cent (8%) unfavorable currency impact, which offset gains from cost efficiency programs and margin improvement. Non-GAAP operating margin rose to 25.2% from 25.9%, measured on a reported basis, so the comparison is affected by the timing and mix of costs as well as currency.
What does exiting the ventilator business mean for Medtronic?
Medtronic will stop developing and selling new ventilators but will continue to honor existing contracts. Management described the product line as increasingly unprofitable and believes existing competitors, which hold most of the market, can meet future demand. Ventilator sales were already declining in the mid-twenties percent in Q3, so the revenue impact should be modest, and the company expects to redirect investment toward the combined ACM business, which includes patient monitoring and airways.
Why is reported FY24 revenue growth lower than organic growth?
The guidance excludes foreign currency and revenue from business separations (reported as 'Other'). Including these items, and at current exchange rates, FY24 reported revenue growth is expected to be 2.9% to 3.3%, versus 4.75% to 5% organic. The gap reflects the divestiture of Renal Care Solutions and other transition manufacturing revenue, plus currency effects.
Is the departure of Robert J. White a concern for investors?
The 8-K states that his position is being eliminated as a result of the PMRI restructuring and the ventilator exit. It is not presented as a performance-related departure. His separation is classified as a termination without cause, so he receives severance under standard executive practices. Investors may want to watch for changes in how the Medical Surgical Portfolio is led following the reorganization.
04—Continue